undamentalytics Newsletter
Sign in

Nano-x Imaging Ltd. (NNOX) stock

Add to watchlist

Add holding +

NASDAQ: NNOX Nasdaq Health Care Equipment Next results ~November 19, 2026

D Fundamentals grade

Nano-x Imaging Ltd. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$0.2

Price-to-sales vs peers

Base case. Range ~$0.2–$1.0. Sales per share times peers' typical price-to-sales; used only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Nano-x Imaging Ltd. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders3 buying, 1 selling10 purchases and 2 sales by directors and officers, last 12 monthsInsider trades
  • Funds52 adding, 74 cuttingOf 16 active managers that changed their stake, 11 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Nano-x Imaging files

Where Nano-x Imaging stands after its latest Filing

Revenue for the twelve months was $13m, up 15.4% on a year earlier, faster than the 13.9% growth a quarter earlier. Free-cash-flow margin rose to -345.6% from -4694.7% a year earlier. Operating margin widened to -600.8% from -4720.7%. The diluted share count is up 10.4% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 2 financial-health checks. Our price-to-sales vs peers value is $0.20 a share, against a share price of $0.33.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 19, 2026 (estimated)

Nano-x Imaging Ltd.'s trailing-twelve-month revenue grew 15.4% year on year, with a free-cash-flow margin of -345.6%. Where it lags: gross margin of -98.2% ranks 122 of 123 health care equipment companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 14.3% while net income fell 40.2%: a 26pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 15.4% over the last 12 months, against a median of 9.1% for health care equipment companies we cover.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Loss-making. Operating margin is -600.8%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 97.9 points on a year ago.
  • Burning cash. Free cash flow was -345.6% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 32.2% of revenue, against a median of 6.1% for health care equipment companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 10.4% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 100% and a beta of 1.2 against the S&P 500.

Latest results

Earnings per share
-$0.17 against an average estimate of -$0.12: missed by 41.7%
Next report
November 19, 2026; average EPS estimate -$0.14

Nano-x Imaging's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-8.5%
  • 1 week-12.0%
  • 1 month-52.5%
  • This year-89.2%
  • 1 year-91.7%
  • 5 years-98.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$13M
Operating margin
-600.8%
Net margin
-576.1%
EPS (TTM, diluted)
$-1.16

Growth

Revenue growth
+15.4%
Change in growth rate
+1.5 pts
Share count change
+10.4%

Cash

Free cash flow (TTM)
-$45M
FCF margin
-345.6%
Stock pay % of revenue
32.2%

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for NNOX from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Nano-x Imaging Ltd. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Nano-x Imaging Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 11%: the 10-year Treasury yield (4.9%) plus a beta of 1.35 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.2 ~$0.2–$1.0 Included, half weight
Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$0.2 ~$0.2–$1.0 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Nano-x Imaging Ltd. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025
Share price$14.54$7.38$6.37$7.20$2.80
Market value$701m$385m$359m$422m$181m
+ Net debt (− = net cash)−$63m−$31m−$56m−$33m−$46m
Enterprise value$638m$355m$303m$389m$136m
Multiples
Price / sales n/m44.9x36.3x37.4x13.9x
Price / earnings —————
Price / free cash flow —————
EV / EBITDA —————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 19, 2026, before the open. Analysts expect revenue of $5m and EPS of −$0.14 (range −$0.14 to −$0.14) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.60 +6% $22m +71%
Next −$0.40 +33% $41m +86%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +25.0% on 90 days ago. In the last 30 days, 0 analysts raised Nano-x Imaging Ltd.'s forecast and 1 cut it.

Consensus EPS forecast Nano-x Imaging Ltd., last 90 days
−$0.60 −$0.40 −$0.20 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.48 Current fiscal year, 60 days ago: −$0.48 Current fiscal year, 30 days ago: −$0.48 Current fiscal year, 7 days ago: −$0.48 Current fiscal year, Now: −$0.60 −$0.60 Next fiscal year, 90 days ago: −$0.20 Next fiscal year, 60 days ago: −$0.30 Next fiscal year, 30 days ago: −$0.30 Next fiscal year, 7 days ago: −$0.30 Next fiscal year, Now: −$0.40 −$0.40

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.48−$0.20
60 days ago −$0.48−$0.30
30 days ago −$0.48−$0.30
7 days ago −$0.48−$0.30
Now −$0.60−$0.40

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.12 −$0.17 −41.7%
Mar 2026 −$0.14 −$0.16 −14.3%
Dec 2025 −$0.15 −$0.17 −13.3%
Sept 2025 −$0.17 −$0.15 +14.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

3 analysts, Oct 2026
Buy267%
Hold133%
Sell00%

Monthly trend

  1. Oct 2026213
  2. Sep 2026213

Counts of recommendations published by analysts covering Nano-x Imaging Ltd., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
7.8%
of tradable shares
Days to cover
7.13
at average volume
Short interest, 1 month
−10%
to October 15, 2026
Held by institutions
12%
of shares
Held by insiders
9.2%
of shares
Employees
197
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
NNOX−68%−49%−14%+13%−61%−89%
Industry peers (median)−7%−37%−8%−20%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
NNOX25%50%33%33%42%9%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
NNOX−84%−60%−77%−56%−72%−91%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since August 21, 2020: 100% from January 27, 2021 to November 2, 2026. Getting back needed a 29499% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.30 – $4.55
From 52-week high
−93.4%
vs 50-day average
−51.4%
vs 200-day average
−80.9%
Volatility (1 year)
100%
Beta vs S&P 500
1.22

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Nano-x Imaging Ltd. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Nano-x Imaging Ltd.
$0 $5M $10M $15M FY21 Q4 FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 Revenue (TTM), FY21 Q4: $1.3M Revenue (TTM), FY22 Q4: $8.6M Revenue (TTM), FY23 Q4: $9.9M Revenue (TTM), FY24 Q4: $11.3M Revenue (TTM), FY25 Q4: $13M $13M

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Revenue (TTM)
FY21 Q4 $1.3M
FY22 Q4 $8.6M
FY23 Q4 $9.9M
FY24 Q4 $11.3M
FY25 Q4 $13M
Revenue growth, TTM YoY Nano-x Imaging Ltd.
0% 200% 400% 600% FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 Revenue growth, TTM YoY, FY22 Q4: 557.8% Revenue growth, TTM YoY, FY23 Q4: 15.5% Revenue growth, TTM YoY, FY24 Q4: 13.9% Revenue growth, TTM YoY, FY25 Q4: 15.4% 15.4%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Revenue growth, TTM YoY
FY22 Q4 557.8%
FY23 Q4 15.5%
FY24 Q4 13.9%
FY25 Q4 15.4%
Operating margin (TTM) Nano-x Imaging Ltd.
-6000% -4000% -2000% 0% FY21 Q4 FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 Operating margin (TTM), FY21 Q4: -4720.7% Operating margin (TTM), FY22 Q4: -1372.2% Operating margin (TTM), FY23 Q4: -631.9% Operating margin (TTM), FY24 Q4: -502.9% Operating margin (TTM), FY25 Q4: -600.8% -600.8%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Operating margin (TTM)
FY21 Q4 -4720.7%
FY22 Q4 -1372.2%
FY23 Q4 -631.9%
FY24 Q4 -502.9%
FY25 Q4 -600.8%
FCF margin (TTM) Nano-x Imaging Ltd.
-6000% -4000% -2000% 0% FY21 Q4 FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 FCF margin (TTM), FY21 Q4: -4694.7% FCF margin (TTM), FY22 Q4: -589.4% FCF margin (TTM), FY23 Q4: -485.4% FCF margin (TTM), FY24 Q4: -348.9% FCF margin (TTM), FY25 Q4: -345.6% -345.6%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period FCF margin (TTM)
FY21 Q4 -4694.7%
FY22 Q4 -589.4%
FY23 Q4 -485.4%
FY24 Q4 -348.9%
FY25 Q4 -345.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 1 9 10 11 13
Gross profit −2 −7 −7 −11 −13
EBITDA −61 −117 −61 −56 −77
Operating income −62 −118 −63 −57 −78
Net income −62 −113 −61 −54 −75
Diluted EPS −$1.28 −$2.17 −$1.08 −$0.91 −$1.16
Growth (year on year)
Revenue — +557.8% +15.5% +13.9% +15.4%
Margins
Gross margin −116.0% −80.2% −66.6% −94.0% −98.2%
EBITDA margin <−999% <−999% −619.8% −493.0% −591.7%
Operating margin <−999% <−999% −631.9% −502.9% −600.8%
Net margin <−999% <−999% −613.6% −474.3% −576.1%
Free-cash-flow margin <−999% −589.4% −485.4% −348.9% −345.6%
Cash flow
Cash from operations −38 −43 −45 −37 −41
Capital spending 23 7 3 3 4
Free cash flow −61 −51 −48 −39 −45
Stock-based pay 19 19 7 7 4
Free cash flow after stock pay −80 −69 −55 −47 −49
Balance sheet
Cash 67 38 56 39 49
Total debt 4 8 — 6 3
Net debt (negative = net cash) −63 −31 −56 −33 −46
Diluted shares 48m 52m 56m 59m 65m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · December 31, 2025
What it owns · $162m
Short-term assets $67mLonger-term assets $95m
What it owes, and who funded it · $162m
Short-term liabilities $17mLonger-term liabilities $6mShareholders' equity $140m
  • Short-term assets cover short-term liabilities $67m of assets due within a year against $17m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $67m short-term assets against $6m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Nano-x Imaging Ltd.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+10.4%
year over year
R&D spending
147.7%
of revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated NNOX HSDT MDAI NSPR HYPR WOK Median
Revenue, last 12 months $13m $12m $15m $11m $17m $10m $99m
Revenue growth, last 12 months 15.4% >999% −44.1% 53.4% 53.2% −14.4% 9.2%
Revenue growth, 3-year average — 142.6% −11.8% 26.6% 19.1% — 13.5%
Revenue growth, latest quarter — >999% −30.4% −0.4% 44.8% — 10.2%
Gross margin −98.2% 95.5% 42.9% 18.1% 51.4% 23.8% 61.2%
Operating margin −600.8% <−999% −77.2% −494.0% −203.3% — −8.5%
Operating margin, 3-year average — <−999% −49.1% −501.9% −323.4% — −17.9%
Net margin −576.1% <−999% −65.5% −484.1% −210.8% −10.9% −12.0%
Cash from operations / revenue −313.3% −223.2% −83.7% −380.1% −163.7% 63.4% −1.9%
Free-cash-flow margin −345.6% −223.2% −84.4% −391.7% −166.5% 49.9% −3.9%
Free-cash-flow margin, 3-year average — <−999% −58.8% −372.4% −279.4% — −7.0%
Stock pay / revenue 32.2% 69.3% 10.0% 98.8% 17.3% — 6.1%
Change in share count 10.4% >999% 38.4% 63.5% 23.9% 128.1% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 15.4% 9.1% 45 of 129
Change in growth rate Growth +1.5pp -0.6pp 37 of 129
Gross margin Profitability -98.2% 61.9% 122 of 123
Operating margin Profitability -600.8% -8.3% 116 of 132
Net margin Profitability -576.1% -12.0% 118 of 133
Free-cash-flow margin Cash generation -345.6% -3.4% 113 of 128
Stock pay as % of revenue Cash generation 32.2% 6.1% 106 of 123
Change in share count Balance sheet 10.4% 3.3% 83 of 115

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$11.2M
Institutions reporting
100
Shares held vs prior quarter
▼ 46.0%
Positions opened / closed
22 / 46

Top buyers and sellers, Q2 2026: 52 institutions bought and 74 sold ; the biggest buyer was Marshall Wace, LLP (+778K shares) and the biggest seller Blackrock, Inc (−3.2M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
UBS Group AG $1.7M 1.5M 15.3% ▲ 9.5%
ARK Investment Management LLC $935,672 807K 8.3% ▲ 10.0%
Marshall Wace, LLP $902,963 778K 8.0% New
Morgan Stanley $759,576 655K 6.8% ▲ 37.5%
Blackrock, Inc. $691,399 596K 6.2% ▼ 84.4%
AQR Capital Management LLC $650,294 561K 5.8% ▲ 13.3%
Bank Of America Corp $529,862 457K 4.7% ▼ 5.7%
Goldman Sachs Group Inc $404,345 349K 3.6% ▼ 8.0%
HRT Financial LP $383,000 330K 3.4% New
Susquehanna International Group, LLP $377,362 325K 3.4% ▲ 228.1%
Jain Global LLC $352,872 304K 3.1% New
State Street Corp $325,947 281K 2.9% ▼ 76.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Nano-x Imaging Ltd.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $190,656 10 trades by 3 insiders, last 12 months Insider sales History → $1,119 2 trades by 1 insider · 0% under pre-set plans
Net ▲ $189,537 net buying
Insider Date Trade Shares Price Value
Meltzer Erez Chief Executive Officer October 19, 2026 Buy 25,000 $0.45 $11,250
Meltzer Erez Chief Executive Officer September 15, 2026 Buy 10,000 $0.69 $6,900
Suesskind Dan S Director September 14, 2026 Buy 30,000 $0.75 $22,500
Suesskind Dan S Director September 14, 2026 Buy 30,000 $0.76 $22,800
Meltzer Erez Chief Executive Officer September 10, 2026 Buy 10,000 $0.78 $7,800
Meltzer Erez Chief Executive Officer August 10, 2026 Buy 9,443 $1.03 $9,726
Kainan Noga Director July 28, 2026 Buy 33,000 $0.90 $29,700
Meltzer Erez Chief Executive Officer July 27, 2026 Buy 36,000 $0.93 $33,480
Suesskind Dan S Director July 27, 2026 Buy 25,000 $0.94 $23,500
Suesskind Dan S Director July 27, 2026 Buy 25,000 $0.92 $23,000
Alroy Erez Director June 10, 2026 Sell 469 $1.65 $774
Alroy Erez Director June 10, 2026 Sell 209 $1.65 $345

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Nano-x Imaging Ltd. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Nano-x Imaging Ltd. in brief

What does Nano-x Imaging Ltd. do?
Nano-x Imaging Ltd. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Nano-x Imaging Ltd.'s stock ticker?
Nano-x Imaging Ltd. trades under the ticker NNOX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Nano-x Imaging Ltd.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Nano-x Imaging Ltd. reported revenue of $13M, 15.4% higher than a year earlier, according to its SEC filings.
What is Nano-x Imaging Ltd.'s free cash flow?
Nano-x Imaging Ltd.'s free-cash-flow margin is -345.6% of revenue over the trailing twelve months, ranking 113 of the 128 health care equipment companies we cover.
Who are Nano-x Imaging Ltd.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are UBS Group AG, ARK Investment Management LLC and Marshall Wace, LLP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Nano-x Imaging Ltd.'s market cap?
On December 31, 2025, Nano-x Imaging Ltd.'s market capitalisation was about $181M and net debt of -$45.8M. Market figures come from third-party market data and may be delayed.
Who are Nano-x Imaging Ltd.'s competitors?
In our Health Care Equipment peer group, the companies closest to Nano-x Imaging Ltd. are Solana Co, Spectral AI, Inc., Inspiremd, Inc., Hyperfine, Inc. and Work Medical Technology Group LTD. The side-by-side comparison below sets their revenue, margins and growth against Nano-x Imaging Ltd.'s.
Are insiders buying or selling Nano-x Imaging Ltd. stock?
Over the last 12 months, Nano-x Imaging Ltd.'s directors and officers reported 10 open-market purchases and 2 sales on Form 4. The insider trading page charts every trade.
When is Nano-x Imaging Ltd.'s next earnings date?
Around November 19, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Nano-x Imaging Ltd. announces its own schedule.